Administration of enoxaparin by continuous infusion in a naturalistic setting: Analysis of renal function and safety

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 3, 2005, Pages 207-213

  Kane Gill, S L ^a   Feng, Y ^a   Bobek, M B ^b   Bies, R R ^a   Pruchnicki, M C ^c   Dasta, J F ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Creatinine; Enoxaparin; Intravenous infusions; Kidney failure; Low molecular weight heparin; Safety

Indexed keywords

ENOXAPARIN; HEPARIN; TICLOPIDINE; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; CREATININE;

ADULT; AGED; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ORAL BLEEDING; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; WARD; WOUND; ARTICLE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG MONITORING; HOSPITAL; HOSPITAL BED CAPACITY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; UNIVERSITY HOSPITAL;

ANTICOAGULANTS; CREATININE; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FEMALE; HOSPITAL BED CAPACITY, 500 AND OVER; HOSPITALS; HOSPITALS, UNIVERSITY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 23844523646     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00634.x     Document Type: Review

References (39)

1. Wong GC, Giugliano RP, Antman EM (2003) Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. Journal of the American Medical Association, 289, 331-342.
2. Bergmann JF, Mouly S (2002) Thromboprophylaxis in medical patients: focus on France. Seminars in Thrombosis and Hemostasis, 28 (Suppl. 3), 51-55.
3. Hull RD, Raskob GE, Brandt RF et al. (2000) Low-molecular-weight heparins vs. heparin in the treatment of patients with pulmonary embolism. Archives of Internal Medicine, 160, 229-236.
4. Huet Y, Gouault-Heilmann M (1986) Low molecular weight heparin fraction PK 10169: a new therapeutic means for anticoagulant therapy? Haemostasis, 16, 165-172.
5. Lorenzini JL, Freysz M, Honnart D, Zeller V, Dutrillaux F (1991) Continuous hemofiltration with a low molecular weight heparin, enoxaparine: report on two cases. International Journal of Clinical Pharmacology, Therapy, & Toxicology, 29, 89-91.
6. Huet U, Gouault-Heilmann M, Contant G, Brun-Buisson C (1987) Treatment of acute pulmonary embolism by a low molecular weight heparin fraction. A preliminary study. Intensive Care Medicine, 13, 126-130.
7. Pedersen PC, Ostergaard PB, Hedner U, Bergqvist D, Matzsch T (1991) Pharmacokinetics of a low molecular weight heparin, logiparin after intravenous and subcutaneous administration in healthy volunteers. Thrombosis Research, 61, 477-487.
8. Bruno R, Baille P, Retout S et al. (2003) Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-segment elevation myocardial infraction. British Journal of Clinical Pharmacology, 56, 407-414.
9. Brophy DF, Wazny LD, Gehr TWB, Comstock TJ, Venitz J (2001) The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy, 21, 169-174.
10. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A (2003) Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. Journal of Clinical Pharmacology, 43, 586-590.
11. Becker RC, Spencer FA, Gibson M et al (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. American Heart Journal, 143, 753-759.
12. Lovenox [package insert] (2003) Bridgewater, NJ: Aventis Pharmaceuticals, INC.
13. The ESPRIT Investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet, 356, 2037-2044.
14. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC (1998) The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Archive of Pathology and Laboratory Medicine, 122, 799-807.
15. Beal SL, Sheiner LB (1992) NONMEM user's guide, Part I. San Francisco: University of California at San Francisco.
16. Feng Y, Bies RR, Bobek MB, Kane-Gill SL (2004) Population pharmacokinetic analysis of enoxaparin in patients receiving continuous infusion. Clinical Pharmacology and Therapeutics, 75,30 (Abstract PI-102).
17. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. Journal of Biopharmaceutics and Pharmacokinetics, 20, 511-528.
18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
19. Brater DC, Chennavasin P (1983) Dosing regimens: determination of creatinine clearance as an index of renal function. Drug use in renal disease. Boston: Adis Health Science Press, 26-29.
20. Power BM, Forbes AM, Heerden PV, Ilett KF (1998) Pharmacokinetics of drugs used in critically III adults. Clinical Pharmacokinetics, 34, 25-56.
21. Dorffler-Mely J, de Jonge E, de Pont AC, Meijers J, Vroom MB, Buller HR, Levi M (2002) Bioavailability of subcutaneous low-molecular weight heparin to patients on vasopressors. Lancet, 359, 849-850.
22. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF (2000) Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy, 20, 771-775.
23. Khazan M, Scheuering S, Adamson R, Mathis AS (2003) Prescribing patterns and outcomes of enoxaparin for anticoagulation of atrial fibrillation. Pharmacotherapy, 23, 651-658.
24. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M (1989) The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thrombosis and Haemostasis, 62, 940-944.
25. Sanderink GJ, Liboux AL, Jariwala N et al. (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clinical Pharmacology and Therapeutics, 72, 308-318.
26. Priglinger U, Delle KG, Geppert A et al. (2003) Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Critical Care Medicine, 31, 1405-1409.
27. Green B, Duffull SB (2003) Development of a dosing strategy for enoxaparin in obese patients. British Journal of Clinical Pharmacology, 56, 96-103.
28. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A (2001) Enoxaparin in unstable angina patients with renal function. International Journal of Cardiology, 80, 81-82.
29. Sanderink GJ, Guimart CG, Ozoux M, Jariwala NU, Shukla UA, Boutouyrie BX (2002) Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thrombosis Research, 105, 225-231.
30. Cadroy Y, Pourrat J, Baladre MF et al. (1991) Delayed elimination of enoxaparine in patients with chronic renal insufficiency. Thrombosis Research, 63, 385-390.
31. Hulot JS, Vantelon C, Urien S et al. (2004) Effect of renal function on the pharmacokinetics of enoxaparin and consequences of dose adjustment. Therapeutic Drug Monitoring, 26, 305-310.
32. Bara L, Leizorovicz A, Picolet H, Samama M (1992) Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin (LMWH) or unfractionated heparin. Thrombosis Research, 65, 641-650.
33. Leizorovicz A, Bara L, Samama MM, Haugh MC (1993) Factor Xa inhibitions: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis, 23(suppl. 1), 89-98.
34. Cornelli U, Fareed J (1999) Human pharmacokinetics of low molecular weight heparins. Seminars in Thrombosis and Hemostasis, 25, 57-61.
35. Cestac P, Bagheri H, Lapeyre-Mestre M et al. (2003) Utilisation and safety of low molecular weight heparins: prospective observational study in medicinal inpatients. Drug Safety, 26, 197-207.
36. Spinler SA, Inverso SM, Chohen M, Goodman SG, Stringer KA, Antman EM (2003) Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. American Heart Journal, 146, 33-41.
37. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, Manthous CA (2004) Anticoagulation in hospitalized patients with renal insufficiency: A comparison of bleeding with unfractionated heparin vs enoxaparin. Chest, 125, 856-863.
38. Dodds A, Nicholls M (1983) Haematological aspects of renal disease. Anaesth Intensive Care, 11, 361-368.
39. Fiaccadori E, Maggiore U, Clima B, Melfa L, Rotelli C, Borghetti A (2001) Incidence, risk factors and prognosis of gastrointestinal hemorrhage complicating acute renal failure. Kidney International, 59, 1510-1519.